Skip to content

Posts tagged ‘industry collaboration’

Industry and academia – stronger together

Derived from proteins made by the body’s immune system, monoclonal antibodies are successful drugs used to treat millions of patients. The MRC/UCB Antibody Discovery Initiative offers academic researchers access to UCB’s high-tech antibody discovery platform. Andrew Popplewell, Head of Antibody Discovery and Engineering at UCB Celltech, explains how the initiative is geared to help promote collaborative research.

Andrew Popplewell

Image credit: Andrew Popplewell.

In the pharmaceutical and biotechnology industry today, collaboration and networking are all-important. And the value of tapping into academic knowledge, expertise, and talent is widely acknowledged.

Read more

Why MRC-industry asset sharing is a win-win for me

Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.

Copyright: Richard Mead

Copyright: Richard Mead

I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more

Fighting cancer like an infection

Professors Irv Weissman and Ravi Majeti at Stanford University and Professor Paresh Vyas at the MRC Molecular Haematology Unit in Oxford, are working on an antibody from the Stanford investigators that enables the immune system to detect and kill cancer cells. They are now testing whether it’s safe and effective for use in people with blood cancer. In this week’s blog they tell us how they collaborated across the Atlantic to get public funding for a project that has led to a spin out with multiple backers and a promising clinical trial.

Immune cells start to recognise and destroy a tumour

What if we could make our immune system fight cancer like it fights infection?

These aren’t the only teams in the world grappling with that question but for Professor Irv Weissman and Professor Paresh Vyas, the solution feels tantalisingly close for patients with blood cancer. Read more